中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

人类免疫缺陷病毒/丙型肝炎病毒混合感染者抗丙型肝炎病毒治疗的进展

田地 徐小元

引用本文:
Citation:

人类免疫缺陷病毒/丙型肝炎病毒混合感染者抗丙型肝炎病毒治疗的进展

基金项目: 

国家自然科学基金(30771906); 高等学校博士学科点专项科研基金(20090001110081); 国家科技重大专项(2008ZX10002-013); 

详细信息
  • 中图分类号: R512.91;R512.63

Treatment of hepatitis C virus infection in HIV/HCV co-infected patients

Research funding: 

 

  • 摘要: 由于人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)有相同的传播途径,HIV/HCV混合感染现象十分普遍,已成为严重的公共卫生问题。高效抗逆转录病毒治疗(HAART)的应用显著减少了与HIV感染相关的发病率和病死率,而HCV混合感染引起的慢性肝脏疾病日益成为HIV/HCV混合感染者发病和死亡的重要因素。HIV/HCV混合感染者HCV相关肝病的风险增加,有效的抗HCV治疗对延长这一人群的生存期至关重要。本文就抗HCV治疗对象的评估、治疗时机的选择、治疗的方法、治疗监测和疗效评估以及治疗注意的问题作一综述。

     

  • [1]王慧, 贾继东.美国肝病学会2009年版丙型肝炎指南要点介绍[J].肝脏, 2009, 14 (3) :231-233.
    [2]Soriano V, Puoti M, Sulkowski M, et al.Care of patients with hepatitis C and HIV-coinfection[J].AIDS, 2004, 18 (1) :1-12.
    [3]Cote P, Baril JG, Hebert MN, et al.Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection:a practical guide for health care professionals[J].Can J Infect Dis Med Microbiol, 2007, 18 (5) :293-303.
    [4]Moodie EE, Pant Pai N, Klein MB.Is antiretroviral therapy causing long-term liver damage?A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts[J].PLoS One, 2009, 4 (2) :e4517.
    [5]中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 12 (4) :194-198.
    [6]Valerio L, Yazdanpanah Y, Poizot-Martin I, et al.Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patientd[J].J Acquir Immune Defic Syndr, 2008, 47 (1) :50-55.
    [7]Opravil M, Sasadeusz J, Cooper DA, et al.Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection[J].J Acquir Immune Defic Syndr, 2008, 47 (1) :36-49.
    [8]Sanchez-Conde M, Berenguer J, Miralles P, et al.Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase[J].Clin Infect Dis, 2006, 43 (5) :640-644.
    [9]Soriano V, Puoti M, Sulkowski M, et al.Care of patients coinfected with HIV and hepatitis C virus:2007 updated recommendations from the HCV-HIV International Panel[J].AIDS, 2007, 21 (9) :1073-1089.
    [10]Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.Peginterferon Alfa-2a plus ribavirin for chronichepatitis C virus infection in HIV-infected patients[J].N Engl J Med, 2004, 351 (5) :438-450.
    [11]Chung RT, Andersen J, Volberding P, et al.Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons[J].N Engl J Med, 2004, 351 (5) :451-459.
    [12]Carrat F, Bani-Sadr F, Pol S, et al.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients:A randomized controlled trial[J].JAMA, 2004, 292 (23) :2839-2848.
    [13]Laguno M, Murillas J, Blanco JL, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients[J].AIDS, 2004, 18 (13) :F27-36.
    [14]赵四海, 刘恩岐, 成大欣, 等.HIV患者合并感染基因1和4型丙型肝炎病毒治疗效果的Meta分析[J].浙江大学学报 (医学版) , 2009, 38 (3) :315-319.
    [15]Dore GJ, Torriani FJ, Rodriguez-Torres M, et al.Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection[J].AIDS, 2007, 21 (12) :1555-1559.
    [16]De Bona A, Galli L, Gallotta G, et al.Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy[J].New Microbiol, 2007, 30 (3) :259-264.
    [17]Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.APRICOT Study Group.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients[J].N Engl J Med, 2004, 351 (5) :438-450.
    [18]Nicot F, Legrand-Abravanel F, Lafont T, et al.Serum J Clini Hepatol, May 2011, Vol.27, No.5concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV[J].J Med Virol, 2008, 80 (9) :1523-1529.
    [19]Rendon AL, Nunez M, Romero M, et al.Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients[J].J Acquir Immune Defic Syndr, 2005, 39 (4) :401-405.
    [20]Laguno M, Larrousse M, Murillas J, et al.Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin[J].J Acquir Immune Defic Syndr, 2007, 44 (2) :174-178.
    [21]Lafeuillade A, Hittinger G, Chadapaud S.Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection[J].Lancet, 2001, 357 (9252) :280-281.
    [22]Kakuda T, Brinkman K.Mitochondrial toxicity effects of ribavirin[J].Lancet, 2001, 357 (9270) :1802-1803.
    [23]Bani-Sadr F, Carrat F, Rosenthal E, et al.Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment[J].Clin Infect Dis, 2005, 41 (12) :1806-1809.
    [24]Reiberger T, Kosi L, Maresch J, et al.Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy[J].J Infect Dis, 2010, 202 (1) :156-160.
    [25]Alvarez D, Dieterich DT, Brau N, et al.Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons[J].J Viral Hepat, 2006, 13 (10) :683-689.
    [26]Vispo E, Barreiro P, Pineda JA, et al.Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir[J].Antivir Ther, 2008, 13 (3) :429-437.
    [27]Bani-Sadr F, Denoeud L, Morand P, et al.Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination:does abacavir play a role?[J].J Acquir Immune Defic Syndr, 2007, 45 (1) :123-125.
    [28]Amorosa VK, Slim J, Mounzer K, et al.The influence of abacavir and other antiretroviral agents on virologic response to HCV therapy among antiretroviral-treated HIV-infectrd patients[J].Antivir Ther, 2010, 15 (1) :91-99.
    [29]Laufer N, Laguno M, Perez I, et al.Abacavir dose not influence the rate of sustained virological response in HIV-HCV co-infected patients treated with pegylated interferon and weight adjusted ribavirin[J].Antivir Ther, 2008, 13 (7) :953-957.
    [30]Mira JA, López-Cortés LF, Barreiro P, et al.Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovie plus either lamivudine or emtricitabine as nucleoside analogue backbone[J].J Antimicrob Chemother, 2008, 62 (6) :1356-1373.
  • 加载中
计量
  • 文章访问数:  3624
  • HTML全文浏览量:  29
  • PDF下载量:  877
  • 被引次数: 0
出版历程
  • 出版日期:  2011-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回